Health Care Counsel Blog

815 total results. Page 1 of 33.

Gayland O. Hethcoat II
Who will notify the potentially millions of individuals whose information might have been jeopardized by the massive cyberattack on Change Healthcare? Since the affiliate of UnitedHealth Group (UHG) first reported the cyberattack in February.
D. Jacques Smith, Randall A. Brater, Michael F. Dearington, Nadia Patel, Hillary M. Stemple, M.H. Joshua Chiu, Rebecca W. Foreman
Headlines that Matter for Companies and Executives in Regulated Industries
Anne M. Murphy, Douglas A. Grimm
Recent events have caused hospitals and health systems nationwide to contemplate more robust participation in the long term care (LTC) sector, whether through modified ownership, joint venturing, clinical affiliation, or third-party management.
D. Jacques Smith, Randall A. Brater, Michael F. Dearington, Nadia Patel, Laura Zell
Headlines that Matter for Companies and Executives in Regulated Industries
Douglas A. Grimm, Moyosore O. Koya
On May 7, the Federal Trade Commission (FTC) published a Final Rule banning noncompete covenants for workers, including employees, independent contractors, and volunteers.
Jill A. Steinberg, Gayland O. Hethcoat II, Moyosore O. Koya
On April 26, the US Department of Health and Human Services Office for Civil Rights (OCR) published a Final Rule that adds protections under the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule designed to support the privacy of reproductive health care.
D. Jacques Smith, Randall A. Brater, Michael F. Dearington, Nadia Patel, Heather M. Zimmer, Elizabeth Satarov
Headlines that Matter for Companies and Executives in Regulated Industries
Douglas A. Grimm, Stephanie Trunk, Gayland O. Hethcoat II
Disputes between 340B Drug Pricing Program-covered entities and the drug manufacturers required to sell outpatient drugs to those entities at discounted prices will be governed by an alternative dispute resolution (ADR) process under a Final Rule published on April 19, by the US Department of Health and Human Services’ Health Resources and Services Administration (HRSA).
Katia Asche, Sharon O’Reilly, Lynn R. Fiorentino, Matthew R. Mills
On May 1, the California Supreme Court granted Gilead Science Inc.’s request to review a California appellate court’s holding that the pharmaceutical manufacturer must defend against negligence claims stemming from its decision to postpone marketing a version of an HIV drug.
Alison Lima Andersen, Pascal Naples, Nicole M. Curtis
Last week, the US Court of Appeals for the Fourth Circuit issued a decision holding that state health care plans in North Carolina and West Virginia must cover gender-affirming surgeries.
Thomas E. Jeffry, Jr., Gayland O. Hethcoat II, M.H. Joshua Chiu
On February 14, the US Department of Health and Human Services (HHS) Office for Civil Rights (OCR) issued its annual reports to Congress detailing its actions to enforce the privacy, security, and breach notification requirements under the Health Insurance Portability and Accountability Act (HIPAA).
Caroline Turner English, Alison Lima Andersen, Pascal Naples
In a win for plaintiffs, the US Court of Appeals for the Ninth Circuit recently reversed a district court’s dismissal of key claims in the case of Ryan S. v. UnitedHealth Group, Inc.
D. Jacques Smith, Randall A. Brater, Michael F. Dearington, Nadia Patel, Mattie Bowden
Headlines that Matter for Companies and Executives in Regulated Industries
Michele L. Gipp, Jo-Ann Marchica, Kathryn L. Steffen
With the end of the first quarter of 2024, we highlight five developments, changes, or challenges that health systems, hospitals, nursing homes, clinics, physician practices, health insurers, and other health care providers, companies, and investors may face when entering into health care transactions in the US market.
David P. Grosso, Starshine S. Chun*
The National Institute of Mental Health reported that 16.32% of youth (aged 12-17) in the District of Columbia (DC) experience at least one major depressive episode (MDE).
Michele L. Gipp, Moyosore O. Koya
On March 5, the Federal Trade Commission (FTC), the US Department of Justice (DOJ) Antitrust Division, and the US Department of Health and Human Services (HHS) launched a cross-government inquiry into the role private equity firms, other alternative asset managers, health systems, and private payers play in health care transactions.
Elizabeth Satarov, Michael F. Dearington, Laura Zell, D. Jacques Smith
On March 12, the Second Circuit affirmed in part and reversed in part a district court dismissal of False Claims Act (FCA) claims predicated on alleged Anti-Kickback Statute (AKS) violations.
David S. Greenberg, Douglas A. Grimm, Hillary M. Stemple, Gayland O. Hethcoat II
Change Healthcare, an affiliate of Optum and UnitedHealth Group, processes more than 15 billion health care transactions annually and touches one of every three patient records.
D. Jacques Smith, Mattie Bowden, Rebekkah R.N. Stoeckler, Michelle J. Shapiro
On March 7, Deputy Attorney General Lisa Monaco delivered the keynote remarks at the American Bar Association’s (ABA) 39th National Institute on White Collar Crime.
D. Jacques Smith, Randall A. Brater, Michael F. Dearington, Nadia Patel, Elizabeth Satarov
Headlines that Matter for Companies and Executives in Regulated Industries
D. Jacques Smith, Randall A. Brater, Nadia Patel, Michael F. Dearington, Mattie Bowden
Headlines that Matter for Companies and Executives in Regulated Industries
Stephanie Trunk, Shoshana Golden
Earlier this month, the US District Court for the District of Oregon issued a declaratory judgment invalidating a key component of the Oregon Drug Price Transparency Program.
Cissy Jackson, Daniel Sjostedt*
As we predicted at the end of the 117th Congress, 2023 was a year of progress for advocates of Pharmacy Benefit Manager (PBM) reform.
D. Jacques Smith, Randall A. Brater, Michael F. Dearington, Nadia Patel, Mattie Bowden, Heather M. Zimmer
Headlines that Matter for Companies and Executives in Regulated Industries
Shoshana Golden, Richard J. Berman
The top legal issues in 2024 for the life sciences field reflect the complex and changing legal landscape that the industry is navigating, encompassing drug pricing, regulatory challenges, and broader societal and governance concerns.